Inhibition of IL-17 prevents the progression of traumatic heterotopic ossification

J Cell Mol Med. 2021 Aug;25(16):7709-7719. doi: 10.1111/jcmm.16617. Epub 2021 Jun 29.

Abstract

Traumatic heterotopic ossification (HO) is the abnormal formation of bone in soft tissues as a consequence of injury. However, the pathological mechanisms leading to traumatic HO remain unknown. Here, we report that aberrant expression of IL-17 promotes traumatic HO formation by activating β-catenin signalling in mouse model. We found that elevated IL-17 and β-catenin levels are correlated with a high degree of HO formation in specimens from patients and HO animals. We also show that IL-17 initiates and promotes HO progression in mice. Local injection of an IL-17 neutralizing antibody attenuates ectopic bone formation in a traumatic mouse model. IL-17 enhances the osteoblastic differentiation of mesenchymal stem cells (MSCs) by activating β-catenin signalling. Moreover, inhibition of IL-17R or β-catenin signalling by neutralizing antibodies or drugs prevents the osteogenic differentiation of isolated MSCs and decreases HO formation in mouse models. Together, our study identifies a novel role for active IL-17 as the inducer and promoter of ectopic bone formation and suggests that IL-17 inhibition might be a potential therapeutic target in traumatic HO.

Keywords: IL-17; heterotopic ossification; trauma; β-catenin.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Animals
  • Antibodies, Monoclonal / pharmacology*
  • Disease Models, Animal
  • Female
  • Heterocyclic Compounds, 3-Ring / pharmacology*
  • Humans
  • Interleukin-17 / antagonists & inhibitors*
  • Interleukin-17 / blood
  • Male
  • Mesenchymal Stem Cells / drug effects*
  • Mesenchymal Stem Cells / metabolism
  • Mice
  • Middle Aged
  • Ossification, Heterotopic / blood
  • Ossification, Heterotopic / pathology
  • Ossification, Heterotopic / prevention & control*
  • Osteogenesis*
  • Signal Transduction
  • Young Adult
  • beta Catenin / antagonists & inhibitors*

Substances

  • Antibodies, Monoclonal
  • Heterocyclic Compounds, 3-Ring
  • Interleukin-17
  • XAV939
  • beta Catenin